Valiant Organics Limited
Valiant Organics divested its partnership interest in its subsidiary Dhanvallabh Ventures LLP. The company received 1.86 crore equity shares of Valiant Laboratories Ltd as consideration for this material related party transaction, which requires shareholder approval.
May 19 2026 23:05:00
Valiant Organics Ltd - 540145 - Board Meeting Outcome for Outcome Of The Board Meeting
Valiant Organics Board approved exiting its partnership in Dhanvallabh Ventures LLP (DVLLP), resulting in DVLLP ceasing to be a subsidiary. This material related party transaction, representing 11.34% of Valiant Organics' consolidated net worth, involves consideration in the form of 1.86 crore equity shares of Valiant Laboratories Limited, pending shareholder approval.
May 19 2026 23:05:00
Valiant Organics Limited
Valiant Organics board approved the divestment of its partnership interest in Dhanvallabh Ventures LLP (DVLLP). This will result in DVLLP ceasing to be a subsidiary of the company, subject to shareholder approval and will be settled by transfer of Valiant Laboratories Ltd shares.
May 19 2026 22:05:00
Valiant Organics Limited
Valiant Organics' Board of Directors has initiated the evaluation of potential restructuring options involving the company, its subsidiaries, and associates. This move aims to achieve operational and strategic synergies, simplify the holding structure, and unlock long-term value for shareholders.
May 16 2026 17:05:00
Valiant Organics Limited
Valiant Organics' Board of Directors has given in-principle approval to evaluate potential restructuring options for the company, its subsidiaries, and associates. This aims to unlock long-term value, simplify the existing structure, and achieve operational and strategic synergies.
May 16 2026 17:05:00
Valiant Organics Ltd - 540145 - Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31, 2026
Valiant Organics board approved FY26 consolidated financial results, reporting a net profit of ₹33.23 cr, a turnaround from last year's loss. Q4 FY26 consolidated net profit surged 274.28% YoY to ₹15.72 cr. Additionally, the Pharma Business was identified as a new reportable segment, and auditors were re-appointed with an un-modified opinion.
May 16 2026 17:05:00
Valiant Organics Ltd - 540145 - Board Meeting Intimation for Approval Of Financial Results For The Quarter And Year Ended March 31, 2026 And To Discuss Any Other Business.
Valiant Organics' Board of Directors is scheduled to meet on May 16, 2026. The agenda includes the consideration and approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
May 12 2026 17:05:00
Read More